Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (331-340 of 520) with videos related to

Pageof 52
Sort By:
JACC. Heart Failure|January 5, 2019
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney DiseaseIris E Beldhuis, Peder L Myhre, Brian Claggett, et al.
European Heart Journal. Acute Cardiovascular Care|January 17, 2023
Trajectory and correlates of pulmonary congestion by lung ultrasound in patients with acute myocardial infarction: insights from PARADISE-MIElke Platz, Brian Claggett, Karola S Jering, et al.
American Journal of Nephrology|December 15, 2017
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy TrialFinnian R Mc Causland, Brian Claggett, Marc A Pfeffer, et al.
European Journal of Heart Failure|January 17, 2020
Predictors of sudden cardiac death in high-risk patients following a myocardial infarctionKieran F Docherty, João Pedro Ferreira, Abhinav Sharma, et al.
Journal of Cardiac Failure|May 23, 2023
Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF TrialJohn W Ostrominski, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|April 27, 2010
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programmeSu Min Chang, Christopher B Granger, Peter A Johansson, et al.
European Journal of Heart Failure|April 2, 2010
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programmeNathaniel M Hawkins, Duolao Wang, Mark C Petrie, et al.
American Heart Journal|December 6, 2011
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAkshay S Desai, Eldrin F Lewis, Rebecca Li, et al.
Circulation|July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programSatish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.
Circulation. Heart Failure|October 8, 2009
Predictors of heart failure in patients with stable coronary artery disease: a PEACE studyEldrin F Lewis, Scott D Solomon, Kathleen A Jablonski, et al.
Pageof 52

Showing results (331-340 of 520) with videos related to

Sort By:
Pageof 52
JACC. Heart Failure|January 5, 2019
Efficacy and Safety of Spironolactone in Patients With HFpEF and Chronic Kidney DiseaseIris E Beldhuis, Peder L Myhre, Brian Claggett, et al.
European Heart Journal. Acute Cardiovascular Care|January 17, 2023
Trajectory and correlates of pulmonary congestion by lung ultrasound in patients with acute myocardial infarction: insights from PARADISE-MIElke Platz, Brian Claggett, Karola S Jering, et al.
American Journal of Nephrology|December 15, 2017
Change in Hemoglobin Trajectory and Darbepoetin Dose Approaching End-Stage Renal Disease: Data from the Trial to Reduce Cardiovascular Events with Aranesp Therapy TrialFinnian R Mc Causland, Brian Claggett, Marc A Pfeffer, et al.
European Journal of Heart Failure|January 17, 2020
Predictors of sudden cardiac death in high-risk patients following a myocardial infarctionKieran F Docherty, João Pedro Ferreira, Abhinav Sharma, et al.
Journal of Cardiac Failure|May 23, 2023
Duration of Heart Failure With Preserved Ejection Fraction and Outcomes With Sacubitril/Valsartan: Insights From the PARAGON-HF TrialJohn W Ostrominski, Brian L Claggett, Milton Packer, et al.
European Journal of Heart Failure|April 27, 2010
Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programmeSu Min Chang, Christopher B Granger, Peter A Johansson, et al.
European Journal of Heart Failure|April 2, 2010
Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programmeNathaniel M Hawkins, Duolao Wang, Mark C Petrie, et al.
American Heart Journal|December 6, 2011
Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fractionAkshay S Desai, Eldrin F Lewis, Rebecca Li, et al.
Circulation|July 20, 2007
Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programSatish Kenchaiah, Stuart J Pocock, Duolao Wang, et al.
Circulation. Heart Failure|October 8, 2009
Predictors of heart failure in patients with stable coronary artery disease: a PEACE studyEldrin F Lewis, Scott D Solomon, Kathleen A Jablonski, et al.
Pageof 52